Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 12/20 | 0.58 |
| ▸ | F13A1 | P00488 | 9/20 | 0.58 |
| ▸ | TGM1 | P22735 | 6/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232086 | 0.83 | TGM2 (0.62) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL2169942 | 0.83 | KMT2A (0.45) | PKMSMN1; SMN2POLB | |
| SCHEMBL6896996 | 0.82 | GPR119 (0.44) | TGM2F13A1TGM1GPR119 | |
| SCHEMBL18410584 | 0.80 | TGM2 (0.65) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL710366 | 0.79 | TGM2 (0.64) | TGM2F13A1TGM1PKM | |
| SCHEMBL1684972 | 0.79 | TGM2 (0.69) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL29060791 | 0.79 | TGM2 (0.64) | TGM2F13A1TGM1PKMPOLB | |
| SCHEMBL3910274 | 0.79 | TGM2 (0.64) | TGM2F13A1TGM1PKMSMN1; SMN2 | |
| SCHEMBL5253160 | 0.79 | POLB (0.70) | TGM2F13A1TGM1POLBSTS | |
| SCHEMBL1181084 | 0.79 | PKM (0.73) | TGM2F13A1TGM1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124629-B2 | Naphthylacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2346807-A1 | NAPHTHYLACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-07-27 | — | — | EP | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-06-03 | — | — | US | disclosed |
| WO-2010055005-A1 | NAPHTHYLACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137250-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | TGM2 3214/4885F13A1 344/4885TGM1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.